The Health Insurance Agency wishes to inform beneficiaries that both the intravitreal administration and the cost of the pharmaceutical product Avastin (Bevacizumab) are fully reimbursed by the GHS, provided that the criteria set by the Agency are met.
Specifically, this medicinal product is included in the medicinal products reimbursed by the Agency following a request for pre-authorisation on the basis of the following indications:
- Wet-type age-related macular degeneration
- Macular edema following retinal vein occlusion.
- Diabetic macular edema
- Diabetic retinopathy
Therefore, under no circumstances may beneficiaries be charged for the cost of the medicinal product or the intravitreal administration of the product in question if the administration relates to one of the above indications covered by the scheme.
(ΕΠ/ΣΧ)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source